Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 4;30(11):2019-2026.
doi: 10.1093/ibd/izad276.

Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies

Jared Cooper  1   2 , Ante Markovinovic  1 , Stephanie Coward  1 , Michelle Herauf  1 , Abdel-Aziz Shaheen  1 , Mark Swain  1 , Remo Panaccione  1 , Christopher Ma  1 , Cathy Lu  1 , Kerri Novak  1 , Karen I Kroeker  2 , Siew C Ng  3 , Gilaad G Kaplan  1
Affiliations
Meta-Analysis

Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies

Jared Cooper et al. Inflamm Bowel Dis. .

Abstract

Background: Primary sclerosing cholangitis is a chronic liver disease associated with significant morbidity, mortality, and healthcare utilization. We conducted a systematic review and meta-analysis of population-based studies of the incidence and prevalence of primary sclerosing cholangitis.

Methods: Medline and Embase were systematically searched to identify population-based studies of a defined geographic area and reported the incidence or prevalence of primary sclerosing cholangitis in the general population. Meta-analyses, using random-effects, were performed to calculate overall and country-specific incidence (per 100 000 persons/year) and prevalence rates (per 100 000 persons) with 95% confidence intervals.

Results: The 14 studies on incidence and the 12 for prevalence originated from North America, Asia, Europe, and Oceania. Incidence and prevalence rates of primary sclerosing cholangitis were 0.87 (95% confidence interval, 0.59-1.29) and 13.53 (95% confidence interval, 10.20-17.94) per 100 000 persons, respectively.

Conclusions: Both the prevalence and incidence of primary sclerosing cholangitis is low in the general population. Future studies on the incidence and prevalence of primary sclerosing cholangitis in the general population should be directed at Asia, Africa, and Latin America to allow for a more robust assessment of the global epidemiology of primary sclerosing cholangitis.

Keywords: incidence; prevalence; primary sclerosing cholangitis; systematic review.

Plain language summary

Primary sclerosing cholangitis is a chronic liver disease with complications such as cirrhosis, cancer, and death. This study summarizes the incidence (0.87 per 100 000) and prevalence (13.53 per 100 000) of PSC and highlight needs in research to study the epidemiology of PSC.

PubMed Disclaimer

Conflict of interest statement

G.K. has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer, Sandoz, and Pendophram. G.K. received grants for research from Ferring and for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer, Takeda. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. September 7, 2018.

R.P. reports grants: Abbvie, Janssen, Pfizer, Takeda Pharmaceuticals. Consulting fees: AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pandion, Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, Takeda Pharmaceuticals Speaker fees: Abbvie, Arena Pharmaceuticals, Celgene, Eli Lilly, Ferring, Gilead Sciences, Janssen, Merck, Pfizer, Roche, Sandoz, Shire, Takeda Pharmaceuticals. Advisory boards: Abbvie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Sandoz, Shire, Sublimity Therapeutics, Theravance Biopharma, Takeda Pharmaceuticals. Research/educational support: Abbvie, Ferring, Janssen, Pfizer, Takeda.

A-A.S. reports research grants: Gilead and Intercept. Speaker fees: SCOPE Canada. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. September 7, 2018.

K.N. reports advisory board fees from AbbVie, Janssen, Pfizer, Ferring, Takeda; speaker’s fees from AbbVie, Janssen, Takeda, Pfizer; and research support from AbbVie, Pfizer.

M.S. reports advisory board: Gilead, Intercept, Novartis, Ipsen, Pfizer. Speaker: Gilead, Intercept, Abbott. Clinical trial or research support: Gilead, BMS, CymaBay, Intercept, Genfit, Pfizer, Novartis, Astra Zeneca, GSK, Celgene, Novo Nordisk, Axcella Health Inc., Merck, Galectin Therapeutics, Calliditas Therapeutics.

C.M. report consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; speaker’s fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Takeda, Pendopharm, and Pfizer; royalties from Springer Publishing; research support from Ferring, Pfizer.

K.K. reports research grants: Pfizer.

S.N. has served as speakers for Janssen, Abbvie, Takeda, Ferring, Tilotts, Menarini, Pfizer and has received research grants from Olympus, Ferring, Janssen, and Abbvie. She is scientific cofounder of GenieBiome limited and hold provisional patents for Therapeutic and Diagnostic Use of Bacteria in COVID-19 Infection, Therapeutic and Prophylactic Use of Microorganisms and Fecal Virome and Fecal Fungome and Therapeutic Efficacy of Fecal Microbiota Transplantation in recurrent Clos difficile infections.

Figures

Figure 1.
Figure 1.
A, Forest plot representing incidence rates of included studies and pooled incidence rates. B, Forest Plot representing prevalence rates of included studies and pooled prevalence rates.
See this image and copyright information in PMC

Comment in

References

    1. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M.. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547-2559. - PubMed
    1. Lindor KD, Kowdley KV, Harrison EM.. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110(5):646-659. - PubMed
    1. Trivedi PJ, Crothers H, Mytton J, et al. . Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology. 2020;159(3):915-928. - PubMed
    1. Barberio B, Massimi D, Cazzagon N, et al. . Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865-1877. - PubMed
    1. Mehta TI, Weissman S, Fung BM, et al. . Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta‐analysis. Liver international. 2021;41(10):2418-2426. - PubMed

Publication types